129 related articles for article (PubMed ID: 23448458)
21. α-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease.
Lee HJ; Park HH; Sohn Y; Ryu J; Park JH; Rhee WJ; Park TH
Appl Microbiol Biotechnol; 2016 Dec; 100(24):10395-10402. PubMed ID: 27353764
[TBL] [Abstract][Full Text] [Related]
22. Enzyme-replacement therapy for Anderson-Fabry disease.
Pastores GM; Thadhani R
Lancet; 2001 Aug; 358(9282):601-3. PubMed ID: 11530143
[No Abstract] [Full Text] [Related]
23. Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
Fauchais AL; Prey S; Ouatara B; Vidal E; Sparsa A
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):737-8. PubMed ID: 19925601
[No Abstract] [Full Text] [Related]
24. [Distinct symptoms and important implications in a 42-year-old man].
Picard C; Fouilhoux A; Chazot C; Dijoud F
Nephrol Ther; 2018 May; 14(3):175-177. PubMed ID: 29198960
[No Abstract] [Full Text] [Related]
25. Ultrastructural Evidence of Glycosphingolipid Degradation After Enzyme Replacement Therapy in Patients With Fabry Disease.
Onoue K; Takemura G; Nakano T; Miyazaki N; Tsujimoto A; Watanabe T; Okada H; Kanamori H; Sugiura J; Kanaoka K; Ishihara S; Horii M; Akai Y; Sakaguchi Y; Saito Y
Circ J; 2019 Sep; 83(10):2081. PubMed ID: 30930427
[No Abstract] [Full Text] [Related]
26. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
Senocak Tasci E; Bicik Z
Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
[TBL] [Abstract][Full Text] [Related]
27. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion.
Lenders M; Schmitz B; Brand SM; Foell D; Brand E
J Allergy Clin Immunol; 2018 Jun; 141(6):2289-2292.e7. PubMed ID: 29421273
[No Abstract] [Full Text] [Related]
28. [Priapism: a severe paediatric complication of Fabry disease].
Labarthe F; de Bodman C; Maruani A; Szwarc C; Froissart R; Lorette G; Lardy H
Rev Med Interne; 2010 Dec; 31 Suppl 2():S217-9. PubMed ID: 21211667
[TBL] [Abstract][Full Text] [Related]
29. Anderson-Fabry disease: enzyme replacement therapy.
Leon-Mateos A; Fernández-Redondo V; Beiras A; Toribio J
Acta Derm Venereol; 2004; 84(1):88-9. PubMed ID: 15040494
[No Abstract] [Full Text] [Related]
30. Fabry disease: treatment and diagnosis.
Rozenfeld PA
IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
[TBL] [Abstract][Full Text] [Related]
31. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
Basic-Jukic N; Kes P; Mokos I; Coric M
Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
[No Abstract] [Full Text] [Related]
32. Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha.
Reidt S; Namdar M; Serra A; Krayenbühl PA; Gruner C; Keller DI; Lüscher TF; Schmied C
Intern Med J; 2014 Feb; 44(2):205-7. PubMed ID: 24528819
[No Abstract] [Full Text] [Related]
33. Fabry disease revisited: Management and treatment recommendations for adult patients.
Ortiz A; Germain DP; Desnick RJ; Politei J; Mauer M; Burlina A; Eng C; Hopkin RJ; Laney D; Linhart A; Waldek S; Wallace E; Weidemann F; Wilcox WR
Mol Genet Metab; 2018 Apr; 123(4):416-427. PubMed ID: 29530533
[TBL] [Abstract][Full Text] [Related]
34. Anderson-Fabry disease in children.
Sestito S; Ceravolo F; Concolino D
Curr Pharm Des; 2013; 19(33):6037-45. PubMed ID: 23448455
[TBL] [Abstract][Full Text] [Related]
35. [Cardiac manifestations of Anderson-Fabry disease and efficacy of enzyme replacement therapy].
Hagège A
Rev Med Interne; 2010 Dec; 31 Suppl 2():S238-42. PubMed ID: 21211672
[TBL] [Abstract][Full Text] [Related]
36. Fabry disease in children: agalsidase-beta enzyme replacement therapy.
Borgwardt L; Feldt-Rasmussen U; Rasmussen AK; Ballegaard M; Meldgaard Lund A
Clin Genet; 2013 May; 83(5):432-8. PubMed ID: 22880956
[TBL] [Abstract][Full Text] [Related]
37. Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies.
Brady RO
Acta Paediatr Suppl; 2003 Dec; 92(443):19-24. PubMed ID: 14989461
[TBL] [Abstract][Full Text] [Related]
38. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
[TBL] [Abstract][Full Text] [Related]
39. Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease.
Hopkin RJ; Bissler J; Grabowski GA
Genet Med; 2003; 5(3):144-53. PubMed ID: 12792421
[TBL] [Abstract][Full Text] [Related]
40. Renal complications of Fabry disease.
Basic-Jukic N; Kes P; Coric M; Basic-Kes V
Curr Pharm Des; 2013; 19(33):6046-50. PubMed ID: 23448456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
